Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Third quarter and nine months ended January 31, 2024 (fiscal 2024). The company provides technology-enabled oncology research and drug-discovery services, primarily pharmacology studies, alongside other translational oncology solutions.
Financial performance
| Metric | Three months ended Jan. 31, 2024 | Prior-year quarter | Nine months ended Jan. 31, 2024 | Prior-year period |
|---|---|---|---|---|
| Revenue | $12.0 million | $12.8 million | $36.2 million | $40.8 million |
| Operating loss | $2.6 million | $2.5 million | $7.1 million | $2.7 million |
| Net loss | $2.5 million | $2.4 million | $7.2 million | $2.8 million |
| Net loss per share, diluted | $0.19 | $0.18 | $0.53 | $0.20 |
- Oncology-services gross margin fell to 34.7% from 39.7% in the quarter and to 38.7% from 45.6% for the nine-month period. Management attributed lower margins mainly to reduced revenue against a generally unchanged cost base.
- Quarterly operating expenses declined 4.2% to $14.6 million, including a 31.7% reduction in research and development. Nine-month operating expenses were nearly flat at $43.2 million; lower R&D was offset in part by higher general and administrative and sales and marketing costs.
- Cash used in operating activities was $4.3 million for the nine months, compared with cash provided of $4.7 million a year earlier. Investing activities used $0.9 million; financing activities used $0.4 million, including share repurchases net of option-exercise proceeds.
- Cash and cash equivalents were $4.5 million at January 31, 2024, down from $10.1 million at April 30, 2023. Total assets were $26.8 million; liabilities were $28.8 million, leaving a stockholders’ deficit of $2.1 million. Current assets were $13.2 million and current liabilities $22.0 million, including $13.3 million of deferred revenue.
- The filing reports no off-balance-sheet debt or similar obligations and no conventional borrowings. Operating lease liabilities totaled $7.7 million; finance-lease liabilities are included in other liabilities, with no separate remaining balance clearly provided.
Changes, outlook and risks
- Revenue declined 5.9% in the quarter and 11.4% for the nine months. Management linked the decrease to study cancellations during fiscal 2023, which reduced net bookings and revenue available for conversion in the current year. Pharmacology services, the principal revenue source, declined to $33.9 million from $38.4 million for the nine-month period.
- Management said cash on hand together with expected operating cash flows during fiscal 2025 should fund operations for at least 12 months from the filing date. If revenue expectations are not met, management says cost reductions could be implemented; additional financing may be needed, with no assurance it would be available on acceptable terms.
- The company continues to evaluate strategic options for its drug-discovery business, potentially including a spin-out or capital raise; it provided no specific transaction or financial guidance.
- Risks include revenue and booking variability, ongoing losses and cash consumption, credit losses, and exposure to economic and geopolitical uncertainty, inflation, interest rates and supply-chain disruptions. Management reported no material changes to the risks in its prior annual report.
- Unusual items include an $81,000 loss on disposal of laboratory equipment and software during the nine-month period, and $240,000 of tumor-model royalty expense versus $129,000 a year earlier. The company repurchased approximately 120,300 shares for a total of about $708,000 through January 31, 2024. No litigation was reported; management stated disclosure controls were effective.
Important facts for investors to verify
- Whether bookings, cancellations and revenue conversion improve, and how deferred revenue translates into future recognized revenue and cash receipts.
- Whether operating cash burn moderates and whether the stated 12-month liquidity outlook is supported by actual fiscal 2025 operating cash flows.
- Whether service margins recover as revenue changes, given the relatively fixed cost base.
- Potential financing needs, planned cost reductions, and any developments in strategic options for the drug-discovery business.
- Credit-loss allowances, lease commitments and share-repurchase activity relative to the company’s limited cash balance.